GlassScriptPhysician profile
Mario B Sy
NPI 1447210638
$551.99
in general payments reported to CMS, 2019-2025
13 companies · $283 in 2025
The $283 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $11.50 · 2023: $40.42 · 2024: $217 · 2025: $283.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $540.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $540.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $147.43 | 2024-2025 | |
| Janssen Biotech, INC. | $142.43 | 2024-2025 | Darzalex, Erleada, Imbruvica |
| Daiichi Sankyo INC. | $57.85 | 2024-2025 | Enhertu |
| Exelixis INC. | $41.47 | 2024-2025 | Cabometyx |
| Takeda Pharmaceuticals U.S.A., INC. | $26.19 | 2025 | |
| Geron Corporation | $25.69 | 2025 | Rytelo |
| Horizon Therapeutics Plc | $24.56 | 2023 | Uplizna |
| Eisai INC. | $20.50 | 2025 | |
| Incyte Corporation | $19.88 | 2025 | Zynyz, Monjuvi |
| Sobi, INC | $18.63 | 2024 | |
| Mirati Therapeutics, INC. | $15.86 | 2023 | Krazati |
| Epizyme, INC. | $11.50 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mario Sy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.